Market for inhaled nitric oxide shows consistent growth as the adoption of modern respiratory care treatments increases for the management of serious pulmonary illnesses. Inhaled nitric oxide is commonly used for providing selective vasodilation and improving the process of oxygenation in the lung of patients who suffer from acute respiratory conditions. The use of inhaled nitric oxide in NICUs, intensive care facilities, and special respiratory care units drives the market growth.
Increasing occurrence of pulmonary diseases and breathing complications in children and adults is boosting the need for advanced inhalation therapy treatments globally. More emphasis on advanced respiratory management solutions is being made in healthcare organizations for improving the quality of care and preventing risks associated with hypoxia and pulmonary hypertension.
The Inhaled Nitric Oxide Market size is valued at USD 1.02 Billion in 2025 and is projected to reach USD 2.01 Billion by 2035, growing at a CAGR of 7.15% during the forecast period 2026–2035.
Leading Companies in the Inhaled Nitric Oxide Market
Mallinckrodt Pharmaceuticals plc
Mallinckrodt Pharmaceuticals plc is another prominent company engaged in inhaled nitric oxide products' development and manufacturing. The company offers therapeutic respiratory care solutions aimed at improving oxygenation and pulmonary health of critically ill patients. The high presence in neonatal care and intensive treatment procedures helps maintain a leadership role in this market segment. Constant investments in innovations in respiratory therapy are advantageous for the company's performance.
Linde plc
Linde plc offers medical gas and respiratory care technologies to hospitals and other health care institutions across the globe. The company develops efficient inhaled nitric oxide technologies used in procedures of critical care treatment. Medical gas infrastructure and healthcare delivery systems are the areas of expertise helping the company to achieve its high market performance.
Air Liquide Healthcare
Air Liquide Healthcare develops innovative respiratory and medical gas technologies applicable in the healthcare system in hospitals, intensive care facilities, as well as home healthcare settings. Inhalation technologies and gas delivery technologies are the major aspects of the company's activities. Inhaled nitric oxide systems developed by the company facilitate an efficient pulmonary disease treatment and management.
Vero Biotech LLC
The primary focus of Vero Biotech LLC is the development of highly portable nitric oxide inhalation delivery technologies. The firm is dedicated towards enhancing accessibilities and ease of use when administering the treatment process. Cost-effective treatments in the respiratory system for medical institutions is another major goal of the organization.
Beyond Air Inc
A leader in the research and development of nitric oxide and their application for respiratory and infectious conditions, Beyond Air Inc. works towards the advancement of inhaled nitric oxide therapies. The development of inhalable nitric oxide-based treatments would not have been possible without research and innovation being at its core.
Bellerophon Therapeutics Inc
This firm specializes in providing pulmonary therapy devices. Bellerophon Therapeutics Inc.develops novel nitric oxide delivery methods in order to improve oxygenation and reduce the complications related to respiratory distress and pulmonary hypertension. Clinical research and development of inhaled nitric oxide therapy is continuously carried out by the organization.
Data-backed trends guiding future business opportunities
Growing incidences of hypoxia and acute respiratory distress syndrome (ARDS) among infants are among the major factors driving the growth of the inhaled nitric oxide market. Neonatal intensive care units and hospitals are increasingly adopting inhaled nitric oxide therapies to improve oxygen delivery and pulmonary circulation in critically ill patients suffering from severe respiratory complications.
Another key factor contributing to market expansion is the increasing prevalence of pulmonary hypertension and chronic respiratory disorders. The use of inhaled nitric oxide treatments has been increasing among healthcare professionals in order to treat pulmonary pressure and ensure effective respiratory functioning for critical care patients. Increased knowledge about the health benefits associated with inhaled nitric oxide has contributed to further market growth.
Technological progress in inhaled nitric oxide delivery devices has been a significant factor in helping the market grow as well. The use of more precise and less complex modern inhalation systems and devices that help reduce costs and offer convenient treatment is expected to drive market growth.
Transforming critical respiratory care with advanced inhaled therapies
The competition in the inhaled nitric oxide market will likely remain high, but due to increased investment in critical care technologies and pulmonary treatment research, there will be new growth opportunities available for market players.
As providers become increasingly interested in innovative respiratory care technologies, the market demand for inhaled nitric oxide therapies can be expected to keep growing. Improved technology will continue contributing to the expansion of the inhaled nitric oxide market.
Inhaled nitric oxide treatments have become an important part of critical respiratory care, and with ongoing improvements and developments, inhaled nitric oxide market growth should continue in the coming years.
